1 min read
Add as a preferred source on Google

Health Canada Approves Lilly’s Mounjaro for Cardiovascular Risk Reduction

The indication applies to adults with type 2 diabetes and established cardiovascular disease, with the decision based on SURPASS-CVOT trial results.

An unmarked injection pen beside a red anatomical heart model / TokenPost.ai
An unmarked injection pen beside a red anatomical heart model / TokenPost.ai

Health Canada approved Eli Lilly and Company’s Mounjaro (tirzepatide) to lower the risk of major adverse cardiovascular events among adults with type 2 diabetes and established cardiovascular disease.

Results from the SURPASS-CVOT trial formed the basis for the approval.

Riza Dagoc

Riza Dagoc reports on regulation, investing and the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…